Lebriz USLU BEŞLİ, Sait SAĞER, Kerim SÖNMEZOĞLU, Sertaç ASA, İlhami USLU, Baresh Razavi KHOSROSHAHI, Hüseyin PEHLİVANOĞLU, Ekrem GÜNER, Aslan AYGÜN, Emre KARAYEL, Zübeyr TALAT, Elife AKGÜN, Çetin DEMİRDAĞ, Onur Erdem ŞAHİN

Comparison of Ga-68 PSMA positron emission tomography/computerized tomography with Tc-99m MDP bone scan in prostate cancer patients

Background/aim: The aim of our study was to compare Tc-99m MDP bone scan and Ga-68 PSMA PET/CT in terms of detection ofbone metastasis in prostate cancer patients.Materials and methods: A total of 28 prostate cancer patients with bone scan and PSMA PET/CT performed within 90 days wereretrospectively included in our analysis. All bone lesions were scored as negative (score-0), positive (score-1), or suspicious (score-2) formetastasis by two experienced nuclear medicine physicians. Both patient-based and region-based analyses were made for all osseouslesions.Results: On per-patient analysis; sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracywere 72.7%, 52.9%, 50%, 75%, and 60.7%, respectively, for bone scan and 90.9%, 100%, 100%, 94.4%, and 96.4%, respectively, forPSMA PET/CT. On per-region analysis; sensitivity, specificity, PPV, NPV, and accuracy were 76.2%, 80.9%, 57.1%, 91.1%, and 79.8%,respectively, for bone scan and 85.7%, 100%, 100%, 95.5%, and 95.4%, respectively, for PSMA PET/CT.Conclusion: Ga-68 PSMA PET/CT has higher sensitivity, specificity, and accuracy compared to bone scan in terms of bone metastasisdetection in prostate cancer patients. Therefore, it might be the modality of choice for patients with suspicion for metastatic disease,despite negative bone scan and conventional imaging results.

PDF

___

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108. doi:10.3322/caac.21262
2. Atan A, Güzel Ö. How should prostate specific antigen be interpreted? Turk J Urol 2013; 39: 188-93. doi:10.5152/tud.2013.038
3. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L et al. Prevention and early detection of prostate cancer. Lancet Oncol 2014; 15: 484-92. doi:10.1016/S1470-2045(14)70211-6
4. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A. Novel approaches to improve prostate cancer diagnosis and management in earlystage disease. BJU Int 2012; 109: 1-7. doi:10.1111/j.1464- 410X.2011.10870.x
5. Li Q, Xiang F, Lin X, Grajo JR, Yang L, Xu Y, Duan Y, Vyas U, Harisinghani M, Mahmood U et al. The role of imaging in prostate cancer care pathway: novel approaches to urologic management challenges along 10 imaging touch points. Urology 2018; 119: 23-31. doi:10.1016/j.urology.2018.04.026
6. Langsteger W, Rezaee A, Pirich C, Beheshti M. (18)F-NaFPET/CT and (99m)Tc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med 2016; 46: 491-501. doi:10.1053/j.semnuclmed.2016.07.003
7. Barinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012; 19: 856-870.
8. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19: 825-33. doi:10.1016/S1470-2045(18)30198-0
9. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300. doi:10.3322/caac.20073
10. Zamboglou C, Schiller F, Fechter T, Wieser G, Jilg CA, Chirindel A, Salman N, Drendel V, Werner M, Mix M et al. (68)GaHBED-CC-PSMA PET/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison. Theranostics 2016; 6: 1619-28. doi:10.7150/thno.15344
11. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kubler H, Beer AJ et al. Diagnostic Efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016; 195: 1436-1443. doi:10.1016/j.juro.2015.12.025
12. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE et al. Impact of (68)Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. Journal of nuclear medicine: official publication. Society of Nuclear Medicine 2018; 59: 434-441. doi:10.2967/jnumed.117.202945
13. Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A, Obek C, Kural AR. The role of PSMA PET/ CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Nucl Med Commun 2017; 38: 149-55. doi:10.1097/MNM.0000000000000617
14. Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, Halac M, Talat Z, Araman A. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015; 36: 582-587. doi:10.1097/ MNM.0000000000000290
15. Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, Tamaki N, Schwaiger M, Maurer T, Eiber M. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. European journal of nuclear medicine and molecular imaging 2016; 43: 2114-2121. doi:10.1007/s00259- 016-3435-0
16. Janssen JC, Meissner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR. Comparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: additional value of morphologic information from low dose CT. European radiology 2018; 28: 610-9. doi:10.1007/s00330-017- 4994-6
17. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-2994.
18. Rigaud J, Tiguert R, Le Normand L, Karam G, Glemain P, Buzelin JM, Bouchot O. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 2002; 168: 1423-1426. doi:10.1097/01.ju.0000030900.55714.76